Text Size

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study

Ansari E., Pavicic-Astalos J., Ayan F., King A.J., Kinsella M., Ng E., Nita A., The VISIONARY Group


  • 2021
  • Advances in Therapy
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Ansari, E., Maidstone and Tunbridge Wells NHS Trust, University of Kent at Canterbury, Kent, United Kingdom; Pavicic-Astalos, J., Institute of Eye Surgery, UPMC Whitfield, Waterford, Ireland; Ayan, F., Santen UK Ltd, St Albans, United Kingdom; King, A.J., Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; Kinsella, M., Buckinghamshire Healthcare NHS Trust, Stoke Mandeville Hospital, Aylesbury, Buckinghamshire, United Kingdom; Ng, E., Institute of Eye Surgery, UPMC Whitfield, Waterford, Ireland; Nita, A., Royal Victoria Infirmary, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom; The VISIONARY Group

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.


Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.


Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022